New combo therapy aims to shield kidneys in african american veterans
NCT ID NCT07155694
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests two drugs, finerenone and empagliflozin, in 30 African American veterans with diabetic kidney disease. The goal is to see if these drugs reduce kidney cell damage by measuring specific proteins in urine. Participants will take one or both drugs for 4 months to check for protective effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Finerenone (Kerendia) and Empagliflozin (Jardiance)
What this could lead to
If successful, this could show that finerenone, alone or with empagliflozin, helps protect kidney health in African American veterans with diabetic kidney disease.
What could go wrong
This is a small early-phase trial with only 30 participants, so results may not apply to everyone. The study looks at markers in urine, not long-term outcomes like kidney failure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington DC Veterans Affairs Medical Center (688)
Washington D.C., District of Columbia, 20422, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••